Effects of tDCS on Depressive Symptoms of Participants With Temporal Lobe Epilepsy

• ClinicalTrials.gov Identifier: NCT03871842
• Recruitment Status: Unknown
• First Posted: March 12, 2019
• Last Update Posted: March 12, 2019
• Sponsor: Hospital de Clinicas de Porto Alegre
• Information provided by (Responsible Party): Hospital de Clinicas de Porto Alegre

Study Description

Brief Summary:

This project was developed to analyze the clinical, biochemical and functional impact of tDCS on depressive symptoms in participants with temporal lobe epilepsy, intending to collaborate directly in the development of new therapeutic strategies for participants with epilepsy and associated mood disorders. Another objective of this work is to add knowledge about biosafety, possible behavioral and electrophysiological effects of tDCS in participants with temporal lobe epilepsy. Depending on the findings, the study as proposed may provide immediate results for the care of participants with epilepsy.

Condition or disease	Intervention/treatment	Phase
Depressive Symptoms; Epilepsy, Temporal Lobe	Device: active tDCS; Device: sham tDCS	Not Applicable

Detailed Description:

Transcranial direct current stimulation (tDCS) has emerged as an alternative tool in the treatment of participants with mood disorders and may also benefit the treatment of participants with epilepsy. However, this therapeutic tool has been little explored in the treatment of mood disorders in participants with epilepsy. Considering these aspects, the main objective of this project is to study the safety and possible therapeutic effects of tDCS in depressive symptoms of participants with temporal lobe epilepsy. As secondary objectives, stands out the evaluation of the effects of this stimulation on the frequency of epileptic seizures and on electrophysiological and biochemical parameters in these participants. To do this, after performing semi-structured interviews to evaluate depressive symptoms, quality of life and sleep, participants with Temporal Lobe Epilepsy will be randomized into two groups: 1) intervention with tDCS in participants with Temporal Lobe Epilepsy and depressive symptoms (T) and 2) sham intervention in participants with Temporal Lobe Epilepsy and depressive symptoms (S). After studying and characterizing the behavioral, biochemical and electroencephalic patterns (EEG), the T group will be submitted to tDCS. The control group will perform the same assessments and the same preparatory procedures, but will not receive the electrical stimulus. Finally, in addition to the analysis of the electroencephalographic patterns of the two groups at the end of each session, the analysis of the brain-derived Neurotrophic Factor Neurotrophic Factor (BDNF) will also be performed, as well as a new clinical evaluation regarding the frequency of seizures and patterns of these participants through the same semi-structured interviews conducted initially.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 60 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Study on the Safety and Effects of Transcranial Direct Current Stimulation (tDCS) in the Treatment of Depressive Symptoms in Participants With Temporal Lobe Epilepsy: A Randomized, Double-blind, Sham-controlled Clinical Trial
• Actual Study Start Date: July 1, 2018
• Estimated Primary Completion Date: April 1, 2019
• Estimated Study Completion Date: July 1, 2019

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: active tDCS; 20-minute of daily anodal stimulation (2mA) above the left dorsolateral prefrontal cortex during 5 days per week for 4 weeks.	Device: active tDCS; Considering that the daily outpatient use of tDCS equipment is not feasible for most patients, the Pain and Neuromodulation group of the Hospital de Clínicas de Porto Alegre developed a portable tDCS device for home use that has a safe protocol, in addition of being easy to use so that the patient can use it at home without help. The safety protocol embedded in the device does not, for example, allow the appliance to be used for more than 20 minutes per day. The device can also provide the assisting staff with data such as the time the patient used the equipment, providing an accurate picture of the patient's adherence to this type of equipment. This tDCS equipment for home use has already been validated in a pilot study and will be used in this work.
Sham Comparator: sham tDCS; 20-minute of daily sham stimulation above the left dorsolateral prefrontal cortex during 5 days per week for 4 weeks.	Device: sham tDCS; The sham intervention will be applied exactly equal to active intervention, but the electric stimulus will last just for 30 seconds.

Outcome Measures

Primary Outcome Measures :

1. Change in depressive symptoms, measured by Beck Depression Inventory. [ Time Frame: 2 months ]
   The objective of this work is to evaluate the antidepressant effect of transcranial direct current stimulation in participants with temporal lobe epilepsy, measuring the depressive symptoms by Beck Depression Inventory before and after treatment, which score ranges from 0 to 21. High values represent more severe depressive symptoms.

Secondary Outcome Measures :

1. Seizure frequency measured by crisis diary [ Time Frame: 3 months ]
   To analyze if tDCS improves the frequency of seizures observing the crisis diary during one month before and one month after treatment.
2. Interictal discharge counting, using Electroencephalographic Exam [ Time Frame: 2 months ]
   To evaluate if epilepsy is affected by tDCS, it will be counted how many interictal discharge the participant presents before and after treatment.
3. Brain-Derived Neurotrophic Factor (BDNF) [ Time Frame: 2 months ]
   To explore possible changes of BDNF in the groups at three times (before treatment, after 20 days of treatment and after the follow-up period), and possible correlation with the clinical findings. BDNF will be measured in Picograms Per Millilitre (pg/mL).
4. QOLIE-31 scale [ Time Frame: 2 months ]
   To observe if there is an improvement in the quality of life of these participants, through the increase of points in the Quality of Life in Epilepsy scale (QOLIE-31), which score ranges from 0-100. High values represent better quality of life.
5. Pittsburgh Sleep Quality Questionnaire [ Time Frame: 2 months ]
   To observe if there is improvement in sleep patterns of the participants, through Pittsburgh Sleep Quality Questionnaire, which score ranges from 0 to 21 (high scores represent better quality of sleep).
6. Munich Chronotype Questionnaire (MCTQ) [ Time Frame: 2 months ]
   To observe if there is change in the chronotype of these participants, through Munich Chronotype Questionnaire (MCTQ).

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Patients older than 18 years.
2. Diagnosis of Temporal Lobe Epilepsy based on clinical, electrophysiological, magnetic resonance (MRI) and computed tomography (CT) imaging of the brain.
3. Patients will be selected who are able to adequately complete the self-administered questionnaires and handle the home tDCS equipment.
4. 13 points or more on the Beck Depression Inventory.

Exclusion Criteria:

1. Clinical history suggestive of other paroxysmal abnormalities other than temporal lobe epilepsy, such as syncope, psychogenic seizures, or transient vascular accident;
2. Change in the antiepileptic regime in the last 30 days;
3. History of status epilepticus on last year;
4. Performed vagus nerve stimulation (VNS), Deep Brain Stimulation (DBS) or other neurostimulation <1 year prior to study;
5. Active suicide plane;
6. Contraindication for tDCS, including head injury, metal on the head or any implanted medical device, including pacemakers and cardiac defibrillators;
7. Pregnancy.

Contacts and Locations

Contacts

Contact: Suelen Mota; +55 51 982808017; sumota@hcpa.edu.br

Contact: Marino Bianchin; +55 51 996376969; mbianchin@hcpa.edu.br

Locations

Brazil

Hospital de Clínicas de Porto Alegre; Recruiting

Porto Alegre, Rio Grande Do Sul, Brazil, 90040-000

Contact: HCPA +55 51 3359.8304 hcpa@hcpa.edu.br

Sub-Investigator: Suelen Mota

Sponsors and Collaborators

Hospital de Clinicas de Porto Alegre

Investigators

• Study Chair: Suelen Mota; HCPA

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Mota SM, Amaral de Castro L, Riedel PG, Torres CM, Bragatti JA, Brondani R, Secchi TL, Sanches PRS, Caumo W, Bianchin MM. Home-Based Transcranial Direct Current Stimulation for the Treatment of Symptoms of Depression and Anxiety in Temporal Lobe Epilepsy: A Randomized, Double-Blind, Sham-Controlled Clinical Trial. Front Integr Neurosci. 2021 Dec 8;15:753995. doi: 10.3389/fnint.2021.753995. eCollection 2021.

• Responsible Party: Hospital de Clinicas de Porto Alegre
• ClinicalTrials.gov Identifier: NCT03871842
• Other Study ID Numbers: 2018-0352
• First Posted: March 12, 2019
• Last Update Posted: March 12, 2019
• Last Verified: July 2018

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Epilepsy; Epilepsy, Temporal Lobe; Depression; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Behavioral Symptoms; Epilepsies, Partial; Epileptic Syndromes